Zhang Ao, Zhou Guochun, Hoepping Alexander, Mukhopadhyaya Jayanta, Johnson Kenneth M, Zhang Mei, Kozikowski Alan P
Drug Discovery Program, Department of Neurology, Georgetown University Medical Center, 3900 Reservoir Road Northwest, Washington, DC 20007-2197, USA.
J Med Chem. 2002 Apr 25;45(9):1930-41. doi: 10.1021/jm0105373.
A novel series of conformationally constrained tricyclic tropane analogues, (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes, were prepared, and their abilities to inhibit high-affinity uptake of dopamine (DA), serotonin (5-HT), and norepinephrine (NE) into rat brain nerve endings (synaptosomes) were evaluated. First, a systematic screening of a variety of different substituents on the phenyl ring indicated that the substitution pattern plays an important role in the monoamine transporter activity. Most compounds in this series possessed a very low activity at the DA transporter (DAT) but a good to excellent affinity for the 5-HT transporter (SERT). In the case of para-substituted phenyl analogues, the electronic character of the substituent did not affect uptake inhibition as dramatically as observed in some benztropine analogues. Among these compounds, the 4-bromophenyl and 4-isopropylphenyl analogues 8d and 8j exhibited the highest potency at the SERT with a K(i) value of 10 nM. In the 3,4-disubstituted phenyl series, even more potent and highly selective compounds were discovered. Compound 8o has a K(i) value of 2.3 nM for uptake inhibition at the SERT, a DAT/SERT uptake ratio of 2360, and a NET/SERT uptake ratio of 200. Compound 8p exhibited a K(i) value of 1.8 nM for uptake inhibition at the SERT, a DAT/SERT uptake ratio of 1740, and a NET/SERT uptake ratio of 151. These compounds are 3-4-fold more potent than the antidepressant medication fluoxetine, and the selectivities for SERT over DAT and NET are also better than those of fluoxetine. Second, a variety of functional modifications on the ester moiety were investigated. Substitution by other esters or amides as well as alkenes did not increase potency, while most of the acetates or benzoates (16-21, 23, and 24) and the ketone 28 exhibited significantly improved activity. A good hydrogen-bonding ability of the substituent is believed to be required for high activity. The most potent and selective ligand is compound 23, which displayed a K(i) value of 0.06 nM and has essentially no activity at the DAT or NET. The present results have important implications for drug addiction as well as a number of psychiatric diseases.
制备了一系列新型的构象受限三环托烷类似物,即(Z)-9-(取代芳基亚甲基)-7-氮杂三环[4.3.1.0(3,7)]癸烷,并评估了它们抑制多巴胺(DA)、5-羟色胺(5-HT)和去甲肾上腺素(NE)高亲和力摄取到大鼠脑神经末梢(突触体)中的能力。首先,对苯环上各种不同取代基进行系统筛选表明,取代模式在单胺转运体活性中起重要作用。该系列中的大多数化合物在DA转运体(DAT)上活性很低,但对5-HT转运体(SERT)具有良好至优异的亲和力。对于对位取代的苯基类似物,取代基的电子性质对摄取抑制的影响不像在一些苯海索类似物中观察到的那样显著。在这些化合物中,4-溴苯基和4-异丙基苯基类似物8d和8j在SERT上表现出最高的效力,K(i)值为10 nM。在3,4-二取代苯基系列中,发现了更有效和高度选择性的化合物。化合物8o在SERT上摄取抑制的K(i)值为2.3 nM,DAT/SERT摄取比为2360,NET/SERT摄取比为200。化合物8p在SERT上摄取抑制的K(i)值为1.8 nM,DAT/SERT摄取比为1740,NET/SERT摄取比为151。这些化合物的效力比抗抑郁药物氟西汀高3至4倍,对SERT相对于DAT和NET的选择性也优于氟西汀。其次,研究了酯部分的各种官能团修饰。用其他酯或酰胺以及烯烃取代并没有提高效力,而大多数乙酸酯或苯甲酸酯(16 - 21、23和24)以及酮28表现出显著提高的活性。据信高活性需要取代基具有良好的氢键结合能力。最有效和选择性的配体是化合物23,其K(i)值为0.06 nM,在DAT或NET上基本没有活性。目前的结果对药物成瘾以及许多精神疾病具有重要意义。